BioSpace News Archive

3Spine, Inc., a U.S. medical device company developing total joint replacement for the lumbar spine, has raised $33 million in an oversubscribed Series C private offering.

The novel immune checkpoint inhibitors harness the ability of the immune system to recognize and destroy cancerous cells.

The advent of next generation sequencing has led to identification of multiple novel molecular alterations in cancer.

Etcembly today announced the appointment of Scott Cuthill PhD, as Chief Business Officer (CBO). The Oxford based company is harnessing the power of the adaptive immune system to transform the precision, scale and speed of development of TCR immunotherapies.

The American Urological Association is proud to launch the AUA Institute for Leadership & Business, a new initiative dedicated to providing education, training and resources to support leadership development and business acumen within the urology community.

Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, announced that Mustafa Noor, MD, FACP, joins the Company as Chief Medical Officer, following the decision of current CMO, Dr. Curt Scribner, to retire from the position.

Brings Over 20 Years of Commercial Biotech Experience to Lead Awakn’s Therapeutics Commercialization Activities in the U.S.

PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner Immunomic Therapeutics will be starting a phase 1 clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces having reached an agreement on the reimbursement for Idefirix in Germany with the National Association of Statutory Health Insurance Funds, GKV-Spitzenverband (GKV-SV) effective March 15.

Smith+Nephew, the global medical technology business, announces it has kicked-off the OXINIUM Technology Tour of Change mobile exhibit.